The filing for a mixed shelf offering is typically viewed positively as it provides a company with flexible financing options for its operations, research and development, and potential acquisitions. This can be particularly beneficial for a biotech company like Praxis Precision Medicines, which may require significant capital for its research and development activities. Investors might see this as a sign of the company's growth potential and strategic planning, potentially leading to a positive short-term impact on the stock price.